Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: Interim results from the New Zealand Intensive Medicines Monitoring Programme

Drug Safety

Volumn 28, Issue 5, 2005, Pages 435-442

  Harrison Woolrych, Mira ^a   Herbison, Peter ^a   McLean, Rachael ^a   Ashton, Janelle ^a   Slattery, Jim ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; LACTONES; MALE; MIDDLE AGED; NEW ZEALAND; PRODUCT SURVEILLANCE, POSTMARKETING; PYRAZOLES; QUESTIONNAIRES; SULFONAMIDES; SULFONES;

EID: 19544394710     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200528050-00006     Document Type: Article

References (16)

1. Singh D. Merck withdraws arthritis drug worldwide. BMJ 2004; 329: 816
2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102
3. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80
4. Ketelbey B (Pfizer NZ Ltd). Letter to New Zealand doctors. 2004 Dec 23
5. World Health Organisation. Information exchange system: cyclooxygenase-2 (COX-2) inhibitor medicines. 2005 Feb 28. QSM/MC/IEA.111
6. Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf 2000; 9: 273-80
7. White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclo-oxygenase-2 inhibitor celecoxib. Am J Cardiol 2003; 92: 411-8
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8
9. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73
10. Clark DWJ, Layton D, Shakir SAW. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf 2004; 27 (7): 427-56
11. Drazen JM. COX II inhibitors: a lesson in unexpected problems [online]. Available from URL: http://www.nejm.org [Accessed 2005 Feb 15]
12. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118-23
13. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclo-oxygenase-2 inhibitors and naproxen on the short term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163 (4): 481-6
14. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64
15. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [online]. Available from URL: http://image.thelancet.com [Accessed 2005 Jan 25]
16. Topol EJ. Arthritis medicines and cardiovascular events: "house of coxibs". JAMA 2005; 293 (3): 366-8